BR0316666A - Novo uso de sulfato de dextrano - Google Patents

Novo uso de sulfato de dextrano

Info

Publication number
BR0316666A
BR0316666A BR0316666-0A BR0316666A BR0316666A BR 0316666 A BR0316666 A BR 0316666A BR 0316666 A BR0316666 A BR 0316666A BR 0316666 A BR0316666 A BR 0316666A
Authority
BR
Brazil
Prior art keywords
dextran sulfate
ibmir
medicament
manufacture
pharmaceutically acceptable
Prior art date
Application number
BR0316666-0A
Other languages
English (en)
Other versions
BRPI0316666B8 (pt
BRPI0316666B1 (pt
Inventor
Bo Nilsson
Olle Korsgren
Original Assignee
Prophymed Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prophymed Ab filed Critical Prophymed Ab
Publication of BR0316666A publication Critical patent/BR0316666A/pt
Publication of BRPI0316666B1 publication Critical patent/BRPI0316666B1/pt
Publication of BRPI0316666B8 publication Critical patent/BRPI0316666B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)

Abstract

"NOVO USO DE SULFATO DE DEXTRANO". A presente invenção se refere ao uso de sulfato de dextrano ou de um derivado farmaceuticamente aceitável do mesmo, na fabricação de um medicamento para o tratamento da Imediata Reação Inflamatória Mediada pelo Sangue (IBMIR). Além disso, a invenção se refere ao uso de sulfato de dextrano ou de um derivado farmaceuticamente aceitável do mesmo na fabricação de um medicamento para o tratamento da ruptura morfológica de transplantes de células e de rejeição a enxerto de transplantes de célula causados pela IBMIR. A invenção pode ser aplicada em pacientes que sofrem de diabetes tipo I, em que ilhotas de Langerhans de suínos são transplantadas na sua veia portal. A administração de sulfato de dextrano de acordo com a invenção, inibe e previne a rejeição e destruição das ilhotas transplantadas, tornando possível a normoglicemia nos pacientes.
BRPI0316666A 2002-11-28 2003-11-26 novo uso de sulfato de dextrano BRPI0316666B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0203526A SE525461C3 (sv) 2002-11-28 2002-11-28 Ny användning av dextransulfat
PCT/SE2003/001830 WO2004047848A1 (en) 2002-11-28 2003-11-26 New use of dextran sulfate

Publications (3)

Publication Number Publication Date
BR0316666A true BR0316666A (pt) 2005-10-11
BRPI0316666B1 BRPI0316666B1 (pt) 2018-09-25
BRPI0316666B8 BRPI0316666B8 (pt) 2021-05-25

Family

ID=20289705

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0316666A BRPI0316666B8 (pt) 2002-11-28 2003-11-26 novo uso de sulfato de dextrano

Country Status (26)

Country Link
US (5) US8629123B2 (pt)
EP (1) EP1567171B1 (pt)
JP (2) JP4315908B2 (pt)
KR (1) KR100828807B1 (pt)
CN (1) CN1296051C (pt)
AT (1) ATE359798T1 (pt)
AU (1) AU2003302378B2 (pt)
BR (1) BRPI0316666B8 (pt)
CA (1) CA2507595C (pt)
CY (1) CY1106739T1 (pt)
DE (1) DE60313356T2 (pt)
DK (1) DK1567171T3 (pt)
EA (1) EA010409B1 (pt)
ES (1) ES2285270T3 (pt)
HK (1) HK1087042A1 (pt)
HR (1) HRP20050439B1 (pt)
IL (1) IL168626A (pt)
IS (1) IS2405B (pt)
NO (1) NO326946B1 (pt)
NZ (1) NZ540744A (pt)
PL (1) PL216067B1 (pt)
PT (1) PT1567171E (pt)
SE (1) SE525461C3 (pt)
SI (1) SI1567171T1 (pt)
WO (1) WO2004047848A1 (pt)
ZA (1) ZA200504111B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666840C (en) * 2006-10-20 2015-07-14 The Australian National University Inhibition of degradation of extracellular matrix
US20110008343A1 (en) * 2007-06-08 2011-01-13 Lambris John D Method Of Reducing Tissue Loss In Pancreatic Islet Cell Transplantation
CN102917711A (zh) * 2010-03-12 2013-02-06 澳大利亚国立大学 硫酸乙酰肝素替代疗法
WO2012008908A1 (en) * 2010-07-16 2012-01-19 Tx Medic Ab Cell therapy
CN102973592A (zh) * 2012-11-26 2013-03-20 合肥博太医药生物技术发展有限公司 硫酸葡聚糖在制备治疗糖尿病药物中的应用
SE537742C2 (sv) 2013-05-13 2015-10-13 Tx Medic Ab Dextransulfat för cellmobilisering
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
WO2015190989A1 (en) * 2014-06-12 2015-12-17 Tx Medic Ab The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
CN106573012B (zh) 2014-06-12 2020-02-28 Tx医生公司 平均分子量低于10000Da的硫酸葡聚糖用于诱导受试者中的血管新生的用途
SE538503C2 (en) 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
CN111263636A (zh) * 2017-09-08 2020-06-09 Tx医生公司 硫酸葡聚糖的新用途
SE544768C2 (en) * 2021-03-24 2022-11-08 Tx Medic Ab Combination for treatment of thromboinflammation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
IL88554A0 (en) * 1988-12-01 1989-07-31 Hadassah Med Org Compositions containing a compound binding to a heparin receptor
TW318142B (pt) 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5464815A (en) 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
CN1178070A (zh) * 1996-09-27 1998-04-08 刘春江 组织脏器移植用保存溶液·手术等时组织脏器保护溶液
CN1057192C (zh) * 1997-09-10 2000-10-11 上海长征医院 一种配制多器官保存液的方法

Also Published As

Publication number Publication date
CY1106739T1 (el) 2012-05-23
JP4972113B2 (ja) 2012-07-11
US20160136331A1 (en) 2016-05-19
ATE359798T1 (de) 2007-05-15
US20140094435A1 (en) 2014-04-03
HRP20050439B1 (en) 2007-11-30
US8906884B2 (en) 2014-12-09
DE60313356D1 (de) 2007-05-31
KR100828807B1 (ko) 2008-05-09
NO20052505L (no) 2005-06-20
IS7908A (is) 2005-06-23
BRPI0316666B8 (pt) 2021-05-25
CN1296051C (zh) 2007-01-24
PT1567171E (pt) 2007-07-09
PL216067B1 (pl) 2014-02-28
CA2507595C (en) 2011-11-08
US9364499B2 (en) 2016-06-14
SI1567171T1 (sl) 2007-08-31
KR20050089803A (ko) 2005-09-08
EA200500757A1 (ru) 2005-12-29
AU2003302378A1 (en) 2004-06-18
JP2006509057A (ja) 2006-03-16
US8901104B2 (en) 2014-12-02
IL168626A (en) 2011-06-30
PL376302A1 (en) 2005-12-27
SE0203526D0 (sv) 2002-11-28
JP4315908B2 (ja) 2009-08-19
NZ540744A (en) 2007-02-23
HRP20050439A2 (en) 2005-12-31
HK1087042A1 (en) 2006-10-06
IS2405B (is) 2008-09-15
US10307440B2 (en) 2019-06-04
ZA200504111B (en) 2006-07-26
US8629123B2 (en) 2014-01-14
SE525461C2 (sv) 2005-02-22
BRPI0316666B1 (pt) 2018-09-25
CN1717240A (zh) 2006-01-04
DE60313356T2 (de) 2007-08-16
AU2003302378B2 (en) 2008-02-21
WO2004047848A1 (en) 2004-06-10
ES2285270T3 (es) 2007-11-16
CA2507595A1 (en) 2004-06-10
US20100113389A1 (en) 2010-05-06
US20060111319A1 (en) 2006-05-25
EP1567171A1 (en) 2005-08-31
JP2009167201A (ja) 2009-07-30
SE0203526L (sv) 2004-05-29
EA010409B1 (ru) 2008-08-29
US20140093484A1 (en) 2014-04-03
EP1567171B1 (en) 2007-04-18
NO326946B1 (no) 2009-03-16
SE525461C3 (sv) 2005-03-23
DK1567171T3 (da) 2007-07-16

Similar Documents

Publication Publication Date Title
BR0316666A (pt) Novo uso de sulfato de dextrano
Al-Majed et al. Protective effects of oral arabic gum administration on gentamicin-induced nephrotoxicity in rats
Dinis-Oliveira et al. Acute paraquat poisoning: report of a survival case following intake of a potential lethal dose
Gilbert et al. Prevention of acute aspirin-induced gastric mucosal injury by 15-R-15 methyl prostaglandin E2: an endoscopic study
Barrioz et al. Randomised trial of prevention of biliary stent occlusion by ursodeoxycholic acid plus norfloxacin
JPS62246520A (ja) 白内障の予防及び逆転方法及び眼の組成物
Wurochekke et al. Biochemical effects on the liver and kidney of rats administered aqueous stem bark extract of Xemenia Americana
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
NO20053077L (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
ES2173641T3 (es) Composicion de derivados opiaceos para la fabricacion de medicamentos.
Yu et al. Endogenous superoxide dismutase activation by oral administration of riboflavin reduces abdominal aortic aneurysm formation in rats
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
ATE277628T1 (de) Behandlung von hematopoietischen zellen mit cxcr4 agonisten
Dinc et al. Methylene blue inhibits the inflammatory process of the acetic acid-induced colitis in rat colonic mucosa
Bramley et al. Serum hyaluronate as a marker of hepatic derangement in acute liver damage
BR0001794A (pt) Aplicação de fitosteróides (e seus isÈmeros), ácidofólico, cianocobalamina e piridoxina em fibrasdietéticas (alimentares)
Lee et al. Korean red ginseng ameliorated experimental pancreatitis through the inhibition of hydrogen sulfide in mice
BR0308576A (pt) Compostos: composições farmacêuticas para administração em um mamìfero e métodos para inibir a enzima citocroma p450rai em um mamìfero
Henderson et al. Collapse after intravenous injection of hashish.
Noureldein et al. Promising anti-diabetic effect of dextran sulfate sodium: Is it its clinical come back?
Del Vecchio et al. Low platelet MAO activity in chronic schizophrenics: a long-term effect of neuroleptic treatment?
Suputri et al. Effects of onion extract on hepar histopatology in alloxan-induced diabetic Rattus novergicus
NO983917L (no) Anvendelse av IL-7 for behandling av autoimmune sykdommer og sµrlig insulinavhengig diabetes mellitus
ES2295670T3 (es) Uso de silimarina y carbopol como regenerador de tejido y celulas pancreaticas con secrecion endocrina, dañados por diabetes mellitus.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: TX MEDIC AB (SE)

Free format text: TRANSFERIDO DE: PROPHYMED AB

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/09/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/11/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF